Medicines, reimagined
Targeted + immunotherapy to transform patient lives.
Our goal is to combine the power of targeted and immuno-therapy in a single molecule to treat complex diseases
We are a team of experienced drug developers, passionate about advancing medicines that shift the treatment paradigm. We are currently focused on strategies that target both solid cancers and activates B cells against the tumor. B cells, a type of lymphocytes, have recently been shown clinically to improve survival outcomes in multiple tumors (1-4).
¹Nature. 577, 549-555 (2020); ²Nature. 597, 274-278 (2021); ³Cancer Cell. 41(3):466-489 (2023); ⁴Nat Rev Drug Discov 20, 179–199 (2021).
We leverage patented quantum mechanics and all atomistic simulations platform to design medicines that are effective and safe.
We are clinical stage.
Transformative science
Our lead candidate, AT1965, a small molecule, is currently in Phase 1 clinical trials for advanced solid malignancies. AT1965 inhibits CMTR2, a novel target, in cancer cells, which recruits a B cell immune response. AT-1965 regressed hard-to-treat solid tumors when given as monotherapy in preclinical studies and was synergistic with immune checkpoint inhibitors.
A complete immune response requires all immune cells to participate. Hence, activating T cells, macrophages or NK cells alone only goes half the distance. B cells exert a complete immune response, directly acting on cancer cells, and activating other immune cells. Clinically, B cells is associated with improved survival outcomes in most solid tumors, including breast, sarcoma, HNSCC, cervical, melanoma, etc¹¯³.